News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Analyst calls Amphenol a tradeable long, citing AI, 5G and electrification demand after its post-2025 earnings pullback.
  • Japan Display agreed to sell its Tottori plant, shares jumped 33%, and the handover is expected by end-September.
  • HSBC upgraded Heineken to buy with a €85 target, implying roughly 29% upside ahead of a new CEO.
  • Analyst recommends buying Domino's on a dip, citing stable same-store sales, free cash flow, and valuation near 20x earnings.
  • Berkeley paused land purchases and re-phased its plan to April 2030, citing geopolitical risks and extended construction lead times.

Latest Articles

Pope Leo Warns of a World 'In Flames' at Ash Wednesday Service

Pope Leo Warns of a World 'In Flames' at Ash Wednesday Service

At an Ash Wednesday Mass marking the start of Lent, Pope Leo described a world 'in flames' and said the ashes placed on worshippers' foreheads could symbolize cities destroyed by war, the erosion of international law and damaged ecosystems. Speaking at the Basilica of Santa Sabina, he acknowledged how powerless people can feel amid such destruction…

Warsaw Market Closes Higher as WIG30 Advances 1.75%

Warsaw Market Closes Higher as WIG30 Advances 1.75%

Poland's equity benchmark WIG30 climbed 1.75% at Wednesday's close, led by strength in Basic Materials, Information Technology and Oil & Gas. CCC SA, Orange Polska and KGHM posted the largest gains, while CD Projekt and Cyfrowy Polsat were among the few decliners. Commodities rallied and selected currency pairs moved modestly.

Pfizer Bounce: High Yield and Cheap Multiple Set Up a Mid-Term Long

Pfizer Bounce: High Yield and Cheap Multiple Set Up a Mid-Term Long

Pfizer is offering a beaten-down valuation, a 6%+ yield, and improving clinical momentum. The stock looks attractive for a mid-term swing trade: entry near current levels, stop below the support band, target at a multiple re-rating if product wins and pipeline readouts continue to surprise. This is a trade, not a deep-value buy-and-hold call; risk …

UN rights chief warns after drone strikes kill scores of civilians across Kordofan

UN rights chief warns after drone strikes kill scores of civilians across Kordofan

The U.N. human rights chief has sounded the alarm after reported drone strikes killed at least 57 civilians, including at least 15 children, across four Sudanese states over two days. Attacks allegedly struck a market, a displacement shelter and two primary schools in the Greater Kordofan region as fighting between the Sudanese Armed Forces and the…

Horizon Kinetics Adds One Share of Texas Pacific Land at $425; Company Sees Strategic Moves and Analyst Attention

Horizon Kinetics Adds One Share of Texas Pacific Land at $425; Company Sees Strategic Moves and Analyst Attention

Horizon Kinetics Asset Management LLC, a roughly 10% stakeholder in Texas Pacific Land Corp (NYSE: TPL), reported acquiring a single share of common stock on February 17, 2026, at $425.55. The transaction leaves the firm with 3,479,374 directly held shares. Market metrics show the stock trading modestly above that purchase price and suggest overbou…

UBS Lifts Gilead Price Target to $175 Citing Next-Gen HIV Data

UBS Lifts Gilead Price Target to $175 Citing Next-Gen HIV Data

UBS raised its price target on Gilead Sciences to $175 from $155 and kept a Buy rating, pointing to imminent Phase I data on six-month long-acting HIV treatment candidates as the catalyst. The bank views these data as the next major advance in Gilead's HIV pipeline and a potential lever to sustain revenue past Biktarvy's patent protection through 2…

UBS Sticks With Buy on Savers Value Village, Cites Store Growth Path and Under-penetrated U.S. Opportunity

UBS Sticks With Buy on Savers Value Village, Cites Store Growth Path and Under-penetrated U.S. Opportunity

UBS has reaffirmed a Buy rating on Savers Value Village Inc (SVV) with a $16.00 price objective, implying roughly 46% upside from the prevailing share price of $10.95. The broker points to preliminary fourth-quarter comparable sales gains, a heavy U.S.-focused expansion plan, and the potential for new stores to transition from short-term profitabil…

Palo Alto Networks Tops Q2 Estimates but Cuts Forward Guidance; CEO Says AI Is Not Replacing Cybersecurity

Palo Alto Networks Tops Q2 Estimates but Cuts Forward Guidance; CEO Says AI Is Not Replacing Cybersecurity

Palo Alto Networks reported fiscal second-quarter results that beat analyst expectations on both EPS and revenue, yet the company provided softer-than-expected guidance for the coming quarter and fiscal year. CEO Nikesh Arora pushed back on market concerns that artificial intelligence could render cybersecurity products obsolete, saying customers a…

UBS Lowers Somnigroup Price Target After Modest EPS Trim, Keeps Buy Call

UBS Lowers Somnigroup Price Target After Modest EPS Trim, Keeps Buy Call

UBS reduced its 12-month price target for Somnigroup (SGI) to $115 from $122 while retaining a Buy rating after shaving its 2026 EPS estimate by 3%. The bank justified the adjustment by referencing Somnigroup's conservative 2026 guidance range and several analyst downgrades, but still sees upside tied to Mattress Firm synergies and modest organic g…

UBS Lifts CAVA Group Price Target to $69 as Sales Momentum Builds

UBS Lifts CAVA Group Price Target to $69 as Sales Momentum Builds

UBS increased its price target on CAVA Group Inc to $69 from $66 but kept a Neutral rating, citing improving sales momentum and easier year-over-year comparisons into 2026. The firm raised its sales-driven estimates for 2026 and 2027 while stopping short of a more positive rating until it sees clearer evidence of sustained, outsized growth. Other a…